{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:01Z","timestamp":1791389101769,"version":"4.3.3"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ipsen Biopharmaceuticals"},{"name":"Ipsen Biopharmaceuticals"},{"name":"Ipsen Biopharmaceuticals"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Great Lakes Neurotechnologies"},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ipsen Biopharmaceuticals"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01NS074343"],"award-info":[{"award-number":["R01NS074343"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54NS065701"],"award-info":[{"award-number":["U54NS065701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001595","name":"Dystonia Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001595","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merz Pharmaceutical"},{"name":"Revance Therapeutic"},{"name":"Retrophin and Acorda Therapeutic"},{"DOI":"10.13039\/100001288","name":"Parkinson's Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.parkreldis.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T02:03:52Z","timestamp":1520474632000},"page":"94-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-136X","authenticated-orcid":false,"given":"Alberto J.","family":"Espay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Trosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Comella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2018.03.002_bib1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mds.870120414","article-title":"Teaching tape for the motor section of the Toronto western spasmodic torticollis scale","volume":"12","author":"Comella","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.03.002_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","article-title":"Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy","volume":"120","author":"Jost","year":"2013","journal-title":"J.\u00a0Neural. Transm."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.03.002_bib3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.parkreldis.2018.03.002_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2017.02.042","article-title":"Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: the ANCHOR-CD registry","volume":"376","author":"Trosch","year":"2017","journal-title":"J.\u00a0Neurol. Sci."},{"issue":"7","key":"10.1016\/j.parkreldis.2018.03.002_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.03.002_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Timerbaeva S for the global Dysport cervical dystonia study group. Long-term efficacy and safety of botulinum toxin type A (dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Park. Relat. Disord."},{"issue":"11","key":"10.1016\/j.parkreldis.2018.03.002_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/mds.26760","article-title":"Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial","volume":"31","author":"Poewe","year":"2016","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.03.002_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-000881","article-title":"Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study","volume":"2","author":"Misra","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.parkreldis.2018.03.002_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/467131","article-title":"Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release","author":"Hauser","year":"2014","journal-title":"Parkinsons Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.03.002_bib10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/mds.20914","article-title":"Minimal clinically important change on the unified Parkinson's disease rating scale","volume":"21","author":"Schrag","year":"2006","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.03.002_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson's disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.03.002_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018301160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018301160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:14:36Z","timestamp":1761178476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018301160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":12,"alternative-id":["S1353802018301160"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.03.002","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}